Financial Toxicity in Patients Receiving Cancer Immunotherapy Treatments

Researched by Belong.Life and published by ASCO
RWED of financial toxicity was reported by the majority of cancer pts receiving Immunotherapy drugs for treatment of their solid tumors. 48% of the pts were aware of possible FTs as a result of their diagnosis and therapy. Only 36% received pre-treatment financial advice by their medical team and in those that received it, the FT incidence reported was reduced from 48% to 30% (absolute Down 37.5%) Physicians should be aware of their pts’s possible risks for FTs and relevant advice should be given prior to the immunotherapy drugs commencement.

To the research>

דילוג לתוכן